BUY ANANDA CANNABINOIDS HERE
Our full-spectrum products have multiple cannabinoids, not just one or two. Some CBD companies sell products that only contain CBD. We do not believe that CBD by itself is the optimal way to consume cannabinoids.
PROBLEMS WITH CANNABINOIDS AS MEDICINE
Hundreds of scientific and medical studies describe the profound therapeutic benefits of cannabinoids, substances found exclusively in Cannabis plants. Most healthcare professionals acknowledge the medicinal potential of these substances, but their acceptance as bona fide medicine is hampered by matters like the lack of relevant “evidence-based” human clinical studies. “Evidence based” refers to the systematic application of scientific methods. “Clinical” denotes treating actual patients rather than just doing theoretical or laboratory work.
Organizations and agencies like the American Academy of Family Physicians, the American Academy of Pediatrics, the National Institutes of Health and the White House Office of National Drug Control Policy recognize the medicinal possibilities offered by cannabinoids. But they uniformly emphasize that these substances should be orally administered. One obstacle to creating such formulations is that cannabinoids taken by mouth have proven difficult to get into the bloodstream. Relative to what may be taken by mouth, only lesser, unpredictable amounts will typically reach there. In other words, cannabinoids have very low bioavailability. Achieving precise dosing and predictable therapeutic outcomes is therefore problematic.
INNOVATION AND ACCOMPLISHMENT
ANANDA Scientific is resolving a long-standing problem that restricts the dependable and cost-efficient use of cannabinoids as medicine. The Company has distinctively pursued a science-based approach to create cannabinoid products that are highly bioavailable when consumed by mouth and thus can efficiently get into the bloodstream – for the first time. Its advent portends consistent dosing and predictable therapeutic outcomes.
ANANDA Scientific centers its current activities on a particular non-psychoactive cannabinoid, cannabidiol (“CBD”). CBD occurs in hemp, a Cannabis plant containing such minuscule amounts of tetrahydrocannabinol (THC) that it cannot be used for “getting high” or, in other words, it has no abuse potential. Hemp is grown around the world for its nutritious seeds and oils, along with fiber for textiles and building materials.
In addition, ANANDA Scientific has developed proprietary hemp strains with extraordinary levels of CBD that permit extraction and purification to proceed in a very cost-effective fashion.
Hemp is an important source of CBD and, in the opinion of many healthcare professionals, CBD is the most important cannabinoid from a medicinal perspective. It manifests enticing potential as a therapy for treating many intractable, debilitating and life-threatening conditions. It also appears remarkably safe to use.
ANANDA SCIENTIFIC AND DIABETES
The diabetes problem is enormous in its scope, with approximately 375 million patients worldwide and more than 550 million forecast by 2030. China alone now has 114 million diabetes patients and 200-300 million pre-diabetics (the medical stage immediately preceding diabetes in which blood sugar levels are abnormally high). Approximately 4 million people die each year from it. Diabetes represented at least $465 billion in global healthcare expenditures in 2011. Insulin injections are the principal way in which diabetes is maintained, but many patients remain infirm or are dying due to the inappropriateness of insulin for tactical and economical reasons. There exists an enormous unmet demand for cost-effective oral medicines able to control diabetes, and cannabinoids appear well suited in this purpose.
ANANDA Scientific has unique, intellectual property regarding cannabidiol (CBD)-based diabetes therapy and is pursuing professionally-refereed, science-based clinical work for bringing what it considers an improved and essential way to control diabetes into the medical market place. CBD may even help prevent diabetes.
ANANDA SCIENTIFIC AND CHRONIC PAIN
Chronic pain is an enormous worldwide problem. About 20% of adults suffer from it and 10% are newly diagnosed each year. Chronic pain currently impacts 116,000 Americans, more than 100 million people in China, 55 million in Europe and 61 million in India. The market for pain-relieving medicine is understandably huge, and with its growth is being significantly driven by aging world demographics.
The market for pain-relieving medicines exceeded $20 billion in the United States and $50 billion worldwide in 2011 – and has been growing at 4% per year for a long time.
Opioids accounted for about $9 billion of the $20 billion United States market in 2011, and it continues to dominate as medicine for pain management. The large market share held by opioids is unfortunately been accompanied by an epidemic of overdose deaths, with prescription opioid mortalities in the US now exceeding the number of people dying from heroin and cocaine combined. There were about 16,000 unintentional opioid deaths in 2013. Opioids are also responsible for almost 500,000 emergency room hospital visits each year. In other words, the consequences of opioid use are a public health nightmare. Furthermore, there is a collective cultural fear of opioids in China rooted in the Opium Wars during the 1800s that led to rampant addiction nationwide. Now, pain patients are not offered or refuse opioids. They instead suffer because effective, non- addictive alternatives are not available.
There is a great unmet need for effective therapeutics with minimal abuse potential. In that regard, non-psychoactive and non-addictive cannabidiol (CBD) seems effective and safe. Consequently, ANANDA Scientific has arranged for clinical studies of CBD and pain management at two major Israeli hospitals. CBD as an analgesic will also be pursued in China, where it is a cultural and regulatory fit. Indeed, the Traditional Chinese Medicine Pharmacopeia shows it was used for pain relief over 1,700 years ago.
The market share held by opioids is unfortunately been accompanied by an epidemic of overdose deaths, with prescription opioid mortalities in the US now exceeding the number of people dying from heroin and cocaine combined. There were about 16,000 unintentional opioid deaths in 2013. Opioids are also responsible for almost 500,000 emergency room hospital visits each year. In other words, the consequences of opioid use are a public health nightmare. Furthermore, there is a collective cultural fear of opioids in China rooted in the Opium Wars during the 1800s that led to rampant addiction nationwide. Now, pain patients are not offered or refuse opioids. They instead suffer because effective, non–addictive alternatives are not available. They instead suffer because effective, non–addictive alternatives are not available.